 Opioids for chronic non-cancer pain
A section of the competing interests statement for this Practice
paper (BMJ 2013;346:f2937, doi:10.1136/bmj.f2937) was
inadvertently deleted during the editing and production stages.
The statement should have included the following sentence at
the end: “The Anaesthesiology Unit of the University of Western
Australia, but not SS personally, has received research and travel
funding and speaking and consulting honoraria from Grünenthal,
CSL, Janssen Pharmaceuticals, Mundipharma, Pfizer,
Phosphagenics, and iX Biopharma within the last five years.”
Cite this as: BMJ 2014;349:g4641
© BMJ Publishing Group Ltd 2014
For personal use only: See rights and reprints http://www.bmj.com/permissions
Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4641 doi: 10.1136/bmj.g4641 (Published 15 July 2014)
Page 1 of 1
Corrections
CORRECTIONS
 on 2 June 2019 by guest. Protected by copyright.
http://www.bmj.com/
BMJ: first published as 10.1136/bmj.g4641 on 15 July 2014. Downloaded from 
